Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.

Pharmacogenomics - 1 Apr 2016

Kulkarni Diptee, Song Kijoung, Briley Linda, King Karen, Dabrowski Christine, Mookerjee Bijoyesh, Legos Jeff, Spraggs Colin

Abstract excerpt

AIM: Pyrexia is a common adverse event (AE) on dabrafenib treatment (monotherapy or combination with trametinib). Since germline SNPs and HLA alleles are implicated in drug-induced AEs, this study investigated their association with pyrexia. PATIENTS & METHODS: 1006 melanoma subjects from five dabrafenib-trametinib clinical studies underwent genotyping for genome-wide SNPs, which enabled imputation of 150 HLA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Fever

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Association Studies

Share to HLA Antigens

Share to Imidazoles

Share to Melanoma

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 27023328
DOI: 10.2217/pgs.16.4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.PMID 27023328Read ↗

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.Semantic proximity Read ↗

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study.Semantic proximity Read ↗

Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.Semantic proximity Read ↗

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.Semantic proximity Read ↗

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.Semantic proximity Read ↗

Polymorphisms at site 469 of B-RAF protein associated with skin melanoma may be correlated with dabrafenib resistance: An in silico study.Semantic proximity Read ↗

Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600mut melanoma patients.Semantic proximity Read ↗

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.Semantic proximity Read ↗

Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.Semantic proximity Read ↗

Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.